Solid splenic masses:: Evaluation with 18F-FDG PET/CT

被引:0
作者
Metser, U
Miller, E
Kessler, A
Lerman, H
Lievshitz, G
Oren, R
Even-Sapir, E
机构
[1] Tel Aviv Univ, Dept Nucl Med, Tel Aviv Sourasky Med Ctr, Sackler Fac Med, IL-64239 Tel Aviv, Israel
[2] Tel Aviv Univ, Dept Radiol, Tel Aviv Sourasky Med Ctr, Sackler Fac Med, IL-64239 Tel Aviv, Israel
[3] Tel Aviv Univ, Dept Gastroenterol, Tel Aviv Sourasky Med Ctr, Sackler Fac Med, IL-64239 Tel Aviv, Israel
关键词
hematology; oncology; FDG; PET/CT; spleen;
D O I
暂无
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Our objective was to assess the role of F-18-FDG PET/CT in the evaluation of solid splenic masses in patients with a known malignancy and in incidentally found lesions in patients without known malignancy. Methods: Two groups of patients were assessed: (a) 68 patients with known malignancy and a focal lesion on PET or a solid mass on CT portions of the PET/CT study; and (b) 20 patients with solid splenic masses on conventional imaging without known malignancy. The standard of reference was histology (n = 16) or imaging and clinical follow-up (n = 72). The lesion size, the presence of a single versus multiple splenic lesions, and the intensity of 18F-FDG uptake expressed as a standardized uptake value (SUV) were recorded. The ratio of the SUV in the splenic lesion to the background normal splenic uptake was also calculated. These parameters were compared between benign and malignant lesions within each of the 2 groups of patients and between the 2 groups. Results: The sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of F-18-FDG PET/CT in differentiating benign from malignant solid splenic lesions in patients with and without malignant disease were 100%, 100%, 100%, and 100% versus 100%, 83%, 80%, and 100%, respectively. In patients with known malignant disease, an SUV threshold of 2.3 correctly differentiated benign from malignant lesions with the sensitivity, specificity, PPV, and NPV of 100%, 100%, 100%, and 100%, respectively. In patients without known malignant disease, false-positive results were due to granulomatous diseases (n - 2). Conclusion: F-18-FDG PET can reliably discriminate between benign and malignant solid splenic masses in patients with known F-18-FDG-avid malignancy. It also appears to have a high NPV in patients with solid splenic masses, without known malignant disease. F-18-FDG-avid splenic masses in patients without a known malignancy should be further evaluated as, in our series, 80% of them were malignant.
引用
收藏
页码:52 / 59
页数:8
相关论文
共 50 条
  • [31] 18F-FDG PET/CT evaluation of patients with ovarian carcinoma
    Iagaru, Andrei H.
    Mittra, Erik S.
    McDougall, Iain Ross
    Quon, Andrew
    Gambhir, Sanjiv Sam
    NUCLEAR MEDICINE COMMUNICATIONS, 2008, 29 (12) : 1046 - 1051
  • [32] Pericardial Mucinous Adenocarcinoma on 18F-FDG PET/CT
    Zhang, Guojian
    Wang, Xuemei
    Yuan, Hongwei
    Zhang, Tao
    CLINICAL NUCLEAR MEDICINE, 2014, 39 (04) : 413 - 414
  • [33] The Performance Comparison of 18F-FDG PET/MRI and 18F-FDG PET/CT for the Identification of Pancreatic Neoplasms
    Haiqun Xing
    Haiyan Ding
    Bo Hou
    Zhixin Hao
    Ya Hu
    Wenjia Zhu
    Sayuan Liang
    Feng Feng
    Fang Li
    Yupei Zhao
    Li Huo
    Molecular Imaging and Biology, 2022, 24 : 489 - 497
  • [34] Hepatic Schwannoma on 18F-FDG PET/CT
    Liu, Yachao
    Xu, Baixuan
    CLINICAL NUCLEAR MEDICINE, 2020, 45 (10) : 808 - 810
  • [35] Evaluation of the Outcome of Lung Nodules Missed on 18F-FDG PET/MRI Compared with 18F-FDG PET/CT in Patients with Known Malignancies
    Sawicki, Lino M.
    Grueneisen, Johannes
    Buchbender, Christian
    Schaarschmidt, Benedikt M.
    Gomez, Benedikt
    Ruhlmann, Verena
    Umutlu, Lale
    Antoch, Gerald
    Heusch, Philipp
    JOURNAL OF NUCLEAR MEDICINE, 2016, 57 (01) : 15 - 20
  • [36] 18F-FDG PET/CT in Xanthoma Disseminatum
    Arslan, Esra
    Aksoy, Tamer
    Leblebici, Cem
    Koku-Aksu, Ayse Esra
    Cermik, Tevfik Fikret
    CLINICAL NUCLEAR MEDICINE, 2020, 45 (09) : 681 - 682
  • [37] 18F-FDG PET/CT of Cervical Carcinoma
    Patel, Chirag N.
    Nazir, Sarfraz A.
    Khan, Zubair
    Gleeson, Fergus V.
    Bradley, Kevin M.
    AMERICAN JOURNAL OF ROENTGENOLOGY, 2011, 196 (05) : 1225 - 1233
  • [38] 18F-FDG PET/CT in Urachal Abscess
    Flaus, Anthime
    Longo, Maria-Giulia
    Dematons, Marine
    Granjon, Denise
    Prevot, Nathalie
    CLINICAL NUCLEAR MEDICINE, 2019, 44 (05) : E349 - E350
  • [39] Negative 18F-FDG PET and positive CT and MRI findings in multifocal splenic hamartoma
    Van de Wiele, Christophe
    Verstraete, Koenraad
    Bourgeois, Sophie
    Maes, Alex
    HELLENIC JOURNAL OF NUCLEAR MEDICINE, 2017, 20 (02): : 182 - 183
  • [40] 18F-FDG PET/CT in the Management of Aortitis
    Bruls, Samuel
    Courtois, Audrey
    Nusgens, Betty
    Defraigne, Jean-Olivier
    Delvenne, Philippe
    Hustinx, Roland
    Moutschen, Michel
    Sakalihasan, Natzi
    CLINICAL NUCLEAR MEDICINE, 2016, 41 (01) : 28 - 33